EUVIMEDDescobrir EUVIMED
Open access · CC BY-NC-ND 4.0

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

Liqian Chen, Xinghong Zhou, Yanting You, Jieyu Chen, Baizhao Peng, Yijian Deng, Shuai Ji, Ying Yang, Xiaohu Chen, Huaxi Liu, Shuxuan Yang, Hiu Yee Kwan iD and 5 more

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70288 ↗

At a glance

Journal article in Phytotherapy Research, 2026. Written by Liqian Chen and 16 co-authors. Institution: Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Major MEDLINE topics: 3',5'-Cyclic-AMP Phosphodiesterases, Ventricular Remodeling, Oleanolic Acid. Cited 1 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: the Joint Funds of National Natural Science Foundation of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin (HED) is a natural bioactive compound that possesses a wide range of pharmacological activities. However, the role of HED in cardiac remodeling and its underlying mechanisms remains elusive. This study aimed to investigate the effects of HED on cardiac remodeling and its molecular targets. Experimental Procedure Through models of cells, zebrafish and mice, we investigated the effects of HED on cardiac hypertrophic response. In mice subjected to ISO‐induced hypertrophy, HED was administered orally at doses of 1.25, 2.5, and 5 mg/kg once daily for 3 weeks. HuProt v4.0 20K Human Proteome Microarray was used to identify the molecular target of HED, followed by validation using surface plasmon resonance (SPR), molecular docking, and site‐directed mutagenesis. Key Results HED attenuated hypertrophy and fibrotic responses in vitro and in vivo. Proteome microarrays identified PDE9A as the molecular target of HED. HED directly bound to PDE9A through hydrogen bonds of Asp 293, and inhibited its activity. Functional tests demonstrated that the protective effects of HED were mediated by targeting PDE9A and then activating cGMP‐PKG signaling. Overexpression of PDE9A abolished the protective effect of HED on cardiac remodeling and the activation of the cGMP‐PKG pathway. Conclusions and Implications Our study suggested that HED, as a novel PDE9A inhibitor, ameliorated cardiac hypertrophic response by activating the cGMP‐PKG signaling pathway, presenting a potential therapeutic strategy for heart failure.

Subjects

MeSH terms (MEDLINE)

3',5'-Cyclic-AMP PhosphodiesterasesVentricular RemodelingOleanolic AcidAnimalsMiceHumansZebrafishMolecular Docking SimulationMaleCyclic GMP-Dependent Protein KinasesCyclic GMPMice, Inbred C57BLCardiomegalySignal TransductionPhosphodiesterase InhibitorsMyocytes, Cardiac

Author keywords

cardiac fibrosiscardiac remodelingheart failurehederageninphosphodiesterase 9A

Substances

3',5'-Cyclic-AMP PhosphodiesterasesOleanolic AcidhederageninCyclic GMP-Dependent Protein KinasesCyclic GMPPde9a protein, mousePhosphodiesterase Inhibitors

Authors and institutions

  • Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
  • The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.
  • School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
  • School of Nursing, Henan University of Traditional Chinese Medicine, Zhengzhou, China.

ORCID profiles: Hiu Yee Kwan

Funding

  • the Joint Funds of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province, China
  • Science and Technology Projects of Guangdong Province
  • Guangzhou Science and Technology Plan Project
  • the Major scientific and technological project of Guangzhou Municipal Health Commission
  • Guangzhou Science and Technology Fund
  • Dongguan social development technology program (high level hospital construction project)

Cite

APA

Chen, L., Zhou, X., You, Y., Chen, J., Peng, B., Deng, Y., Ji, S., Yang, Y., Chen, X., Liu, H., Yang, S., Kwan, H. Y., Jin, W., Zhang, L., Wang, Y., Zhao, X., & Liu, Y. (2026). Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A. Phytotherapy Research. https://doi.org/10.1002/ptr.70288

Vancouver

Chen L, Zhou X, You Y, Chen J, Peng B, Deng Y, et al. Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A. Phytotherapy Research. 2026. doi:10.1002/ptr.70288

BibTeX
@article{Chen2026,
  author = {Chen, Liqian and Zhou, Xinghong and You, Yanting and Chen, Jieyu and Peng, Baizhao and Deng, Yijian and Ji, Shuai and Yang, Ying and Chen, Xiaohu and Liu, Huaxi and Yang, Shuxuan and Kwan, Hiu Yee and Jin, Wen and Zhang, Lei and Wang, Yuegang and Zhao, Xiaoshan and Liu, Yanyan},
  title = {Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70288}
}
Start for free →